Integrated sentinel surveillance linking genetic, antigenic, andepidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013-2014 influenza season

Journal of Infectious Diseases

Volumn 212, Issue 5, 2015, Pages 726-739

  Skowronski, Danuta M ^a,b   Chambers, Catharine ^a   Sabaiduc, Suzana ^a   De Serres, Gaston ^c,d   Winter, Anne Luise ^e   Dickinson, James A ^g   Gubbay, Jonathan ^e,f   Fonseca, Kevin ^g,h   Charest, Hugues ^c,i   Krajden, Mel ^a,b   Petric, Martin ^b   Mahmud, Salaheddin M ^j   Van Caeseele, Paul ^j,k   Bastien, Nathalie ^l   Eshaghi, Alireza ^e   Li, Yan ^j,l  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e PUBLIC HEALTH ONTARIO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

^j UNIVERSITY OF MANITOBA   (Canada)

^k CADHAM PROVINCIAL LABORATORY   (Canada)

^l PUBLIC HEALTH AGENCY OF CANADA   (Canada)

more..

Author keywords

Antigenic site; Clade; Genomic sequencing; Hemagglutination inhibition; Influenza; Influenza A subtype; Influenza B lineage; Influenza vaccine; Vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE; VIRUS RNA;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA A VIRUS (H1N1); INFLUENZA B VIRUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHYLOGENY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS; VACCINATION; VIRUS DETECTION; VIRUS STRAIN; CLASSIFICATION; DNA SEQUENCE; EPIDEMIOLOGICAL MONITORING; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGICAL MONITORING; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; RNA, VIRAL; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943339375     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv177     Document Type: Article

References (50)

1. Treanor J. Weathering the influenza vaccine crisis. N Engl J Med 2004; 351:2037-40.
2. Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989; 160:191-8.
3. Robertson JS. Clinical influenza virus and the embryonated hen's egg. Rev Med Virol 1993; 3:97-106.
4. Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM. The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J Gen Virol 1993; 74:2047-51.
5. Rocha EP, Xu X, Hall HE, et al. Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell-and egg-grown viruses. J Gen Virol 1993; 74:2513-8.
6. Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutations in the egg-adapted H3N2 vaccine strain, not antigenic drift in circulating viruses. PLoS One 2014; 9:e92153.
7. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther 2011; 9:669-83.
8. Hensley SE. Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. Curr Opin Virol 2014; 8:85-9.
9. Gupta V, Earl DJ, Deem MW. Quantifying influenza vaccine efficacy and antigenic distance. Vaccine 2006; 24:3881-8.
10. Pan K, Subieta KC, Deem MW. A novel sequence-based antigenic distance measure for H1N1, with application to vaccine effectiveness and the selection of vaccine strains. Protein Eng Des Sel 2011; 24: 291-9.
11. Skowronski DM, Gilbert M, Tweed SA, et al. Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004-2005. Can Commun Dis Rep 2005; 31:181-91.
12. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines 2014; 13:1571-91.
13. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomized double-blind placebocontrolled trials. Euro Surveill 2013; 18:pii:20585.
14. Skowronski DM, De Serres G, Dickinson J, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis 2009; 199:168-79.
15. Janjua NZ, Skowronski DM, De Serres G, et al. Estimates of influenza vaccine effectiveness for 2007-08 from Canada's sentinel surveillance system: cross-protection against major and minor variants. J Infect Dis 2012; 205:1858-68.
16. Skowronski DM, De Serres G, Crowcroft NS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS Med 2010; 7:e1000258.
17. Skowronski DM, Janjua NZ, De Serres G, et al. Effectiveness of AS03-adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011; 342: c7297.
18. Skowronski DM, Janjua NZ, De Serres G, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-11 season. Clinical Infect Dis 2012; 55:332-42.
19. Skowronski DM, Janjua NZ, Sabaiduc S, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-12 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis 2014; 210:126-37.
20. World Health Organization. WHO recommendations on the composition of influenza virus vaccines. http://www.who.int/influenza/vaccines/virus/recommendations/en/index.html. Accessed 5 January 2015.
21. Lin YP, Gregory V, Collins P, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol 2010; 84:6769-81.
22. Cox NJ, Bender CA. The molecular epidemiology of influenza viruses. Semin Virol 1995; 6:359-70.
23. Ndifon W, Wingreen NS, Levin SA. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci U S A 2009; 106:8701-6.
24. Popova L, Smith K, West AH, et al. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One 2012; 7:e41895.
25. Koel BF, Burke DF, Bestebroer TM, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 2013; 342:976-9.
26. Tate MD, Job ER, Deng Y-M, Gunalan V, Maurer-Stroh S, Reading PC. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses 2014; 6:1294-316.
27. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003; 31: 3381-5.
28. The PyMOL Molecular Graphics System. Version 1.6. New York: Schrödinger, 2013.
29. Public Health Agency of Canada. FluWatch. http://www.phac-aspc.gc.ca/fluwatch/13-14/index-eng.php. Accessed 5 January 2015.
30. Epperson S, Blanton L, Kniss K, et al. Influenza activity-United States,2013-14 season and composition of the 2014-15 influenza vaccines. MMWR Morb Mortal Wkly Rep 2014; 63:483-90.
31. Skowronski D, Chambers C, Sabaiduc S, et al. Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada's sentinel surveillance network, January 2014. Euro Surveill 2014; 19: pii:20690.
32. McNeil SA, Shinde V, Andrew M, et al. Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalization, Canada, February 2014. Euro Surveill 2014; 19:pii:20729.
33. Flannery B, Thaker SN, Clippard J, et al. Interim estimates of 2013-14 seasonal influenza vaccine effectiveness-United States, February 2014. MMWR Morb Mortal Wkly Rep 2014; 63:137-42.
34. Turner N, Pierse N, Huang QS, et al. Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalizations and primary care visits in Auckland, New Zealand, in 2014. Euro Surveill 2014; 19:pii:20934.
35. Linderman SL, Chambers BS, Zost SJ, et al. Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci U S A 2014; 111: 15798-803.
36. Skowronski DM, Chambers C, Sabaiduc S, et al. Pre-and post-pandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence by age, during the 2013-2014 epidemic in Canada. J Infect Dis 2015; 211:109-14.
37. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-79.
38. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-9.
39. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 366:685-96.
40. Centers for Disease Control and Prevention. CDC statement on LAIV effectiveness and vaccination of children. http://www.cdc.gov/flu/news/nasal-spray-effectiveness.htm. Accessed 5 January 2015.
41. European Centre for Disease Prevention and Control. Influenza virus characterization. http://www.ecdc.europa.eu/en/healthtopics/seasonal-influenza/epidemiological-data/Pages/Influenza-virus-characterisation.aspx. Accessed 5 January 2015.
42. Castilla J, Martinez-Baz I, Navascues A, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in Navarre, Spain: 2013-14 mid-season analysis. Euro Surveill 2014; 19:pii:20700.
43. Jimenez-Jorge S, Pozo F, de Mateo S, et al. Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study. Euro Surveill 2014; 19:pii:20727.
44. Aquino TL, Brice GT, Hayes S, et al. Influenza outbreak in a vaccinated population-USS Ardent, February 2014. MMWR Morb Mortal Wkly Rep 2014; 63:947-49.
45. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and metaanalysis. Lancet Infect Dis 2012; 12:36-44.
46. Kelly HA, Sullivan SG, Grant KA, Fielding JE. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64 years, 2007-2011. Influenza Other Respir Viruses 2013; 7: 729-37.
47. Public Health Agency of Canada. FluWatch. http://www.phac-aspc.gc.ca/fluwatch/14-15/index-eng.php. Accessed 5 January 2015.
48. Blanton L, Brammer L, Mustaquim D, et al. Update: influenza activity-United States and worldwide, 18 May-20 September 2014. MMWR Morb Mortal Wkly Rep 2014; 63:861-64.
49. Rolfes M, Blanton L, Brammer L, et al. Update: influenza activity-United States, September 28-December 6, 2014. MMWRMorb Mortal Wkly Rep 2014; 63:1189-94.
50. Skowronski DM, Chambers C, Sabaiduc S, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's sentinel physician surveillance network, January 2015. Euro Surveill 2015; 20:pii:21022.